Aligos Therapeutics reported Q4 2025 net loss of USD 19.9 million (USD 1.91 per share) and FY 2025 net loss of USD 24.2 million (USD 2.45 per share). Q4 2025 R&D expenses were USD 17.0 million and G&A expenses were USD 4.9 million, while FY 2025 R&D expenses were USD 69.5 million and G&A expenses were USD 20.7 million. Cash, cash equivalents and investments totaled USD 77.8 million as of Dec. 31, 2025, which Aligos Therapeutics said is expected to fund planned operations into Q3 2026. On the pipeline, Aligos Therapeutics said the Phase 2 B-SUPREME study of pevifoscorvir sodium in chronic HBV completed planned enrollment of 60 HBeAg- participants in January 2026, with HBeAg+ enrollment ongoing; interim analyses are expected in the first and second half of 2026, and topline data for both cohorts are expected in 2027. The company also said it advanced ALG-170675, a dual-mechanism antisense oligonucleotide partnered with Amoytop, into IND-enabling studies, and noted it is evaluating funding options, including potential out-licensing, for ALG-055009. Aligos Therapeutics also announced the appointment of James Hassard as Executive Vice President, Chief Commercial Officer.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aligos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603050800PRIMZONEFULLFEED9665663) on March 05, 2026, and is solely responsible for the information contained therein.
Comments